Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263.

Cells - 21 Jun 2022

Abdelgawad Ibrahim Y, Agostinucci Kevin, Ismail Somia G, Grant Marianne K O, Zordoky Beshay N

Abstract excerpt

Doxorubicin (DOX) induces endothelial cell (EC) senescence, which contributes to endothelial dysfunction and cardiovascular complications. Senolytic drugs selectively eliminate senescent cells to ameliorate senescence-mediated pathologies. Previous studies have demonstrated differences between immortalized and primary EC models in some characteristics. However, the response of DOX-induced senescent ECs to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Human Umbilical Vein Endothelial Cells

Share to Neutrophil, Myeloperoxidase and Oxidative Mechanisms

Share to Phenotype

Share to Proto-Oncogene Proteins c-bcl-2

Share to Sulfonamides

Share to Telomeres, Telomerase, and Senescence

Source

Open in PubMed Open full text

Identifiers

PMID: 35805077
DOI: 10.3390/cells11131992
PMCID: PMC9266052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263.PMID 35805077Read ↗

Translation of Cellular Senescence to Novel Therapeutics: Insights From Alternative Tools and ModelsSemantic proximity Read ↗

Cellular senescence and cardiovascular diseases: moving to the “heart” of the problemSemantic proximity Read ↗

Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cellsSemantic proximity Read ↗

Cellular Senescence Mediates Doxorubicin Chemotherapy-Induced Vascular Endothelial Dysfunction: Translational Evidence of Prevention with Senolytic TreatmentSemantic proximity Read ↗

Apoptosis-resistance of senescent cells is an intrinsic barrier for senolysis induced by cardiac glycosidesSemantic proximity Read ↗

Cellular senescence in cardiac diseasesSemantic proximity Read ↗

Therapeutic Potential of Senolytics in Cardiovascular DiseaseSemantic proximity Read ↗

From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugsSemantic proximity Read ↗

Procyanidin C1 is a natural agent with senolytic activity against aging and age-related diseasesSemantic proximity Read ↗

Comparative Analysis of drugs that improve the Quality of Life and Life ExpectancySemantic proximity Read ↗

Current senolytics: Mode of action, efficacy and limitations, and their future.Semantic proximity Read ↗

Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.